Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Annie Fang

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
American Journal of Therapeutics|September 22, 2006
Pharmacokinetics of an extended release formulation of alprazolam (Xanax XR) in healthy normal adolescent and adult volunteersPaul Glue, Annie Fang, Kuan Gandelman, et al.
Pediatric Research|December 15, 2010
Is erythropoietin the answer?Fernando F Gonzalez, Annie Fang, Donna M Ferriero
Journal of Acquired Immune Deficiency Syndromes (1999)|December 19, 2013
The effects of boceprevir and telaprevir on the pharmacokinetics of maraviroc: an open-label, fixed-sequence study in healthy volunteersManoli Vourvahis, Anna Plotka, Constantino Kantaridis, et al.
Antimicrobial Agents and Chemotherapy|October 2, 2013
Pharmacokinetic interaction between maraviroc and fosamprenavir-ritonavir: an open-label, fixed-sequence study in healthy subjectsManoli Vourvahis, Anna Plotka, Laure Mendes da Costa, et al.
Journal of the International AIDS Society|November 14, 2014
First prospective comparison of genotypic vs phenotypic tropism assays in predicting virologic responses to Maraviroc (MVC) in a phase 3 study: MODERNJayvant Heera, Srinivas Valluri, Charles Craig, et al.
British Journal of Clinical Pharmacology|February 26, 2008
Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjectsEmma Andrews, Bharat D Damle, Annie Fang, et al.
Journal of Clinical Pharmacology|May 21, 2010
Pharmacokinetics of dexrazoxane in subjects with impaired kidney functionMichael E Brier, Shari K Gaylor, J Patrick McGovren, et al.
Clinical Pharmacology in Drug Development|June 25, 2020
Effect of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Intravenous RivipanselBrinda K Tammara, Kelly Ryan, Anna Plotka, et al.
Pediatric Research|June 14, 2018
Predictive value of early EEG for seizures in neonates with hypoxic-ischemic encephalopathy undergoing therapeutic hypothermiaMarie-Coralie Cornet, Archana Pasupuleti, Annie Fang, et al.
The New Microbiologica|April 30, 2019
First prospective comparison of genotypic versus phenotypic tropism assays in predicting virologic responses to maraviroc in a phase 3 studyJayvant Heera, Srinivas R Valluri, Charles Craig, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
American Journal of Therapeutics|September 22, 2006
Pharmacokinetics of an extended release formulation of alprazolam (Xanax XR) in healthy normal adolescent and adult volunteersPaul Glue, Annie Fang, Kuan Gandelman, et al.
Pediatric Research|December 15, 2010
Is erythropoietin the answer?Fernando F Gonzalez, Annie Fang, Donna M Ferriero
Journal of Acquired Immune Deficiency Syndromes (1999)|December 19, 2013
The effects of boceprevir and telaprevir on the pharmacokinetics of maraviroc: an open-label, fixed-sequence study in healthy volunteersManoli Vourvahis, Anna Plotka, Constantino Kantaridis, et al.
Antimicrobial Agents and Chemotherapy|October 2, 2013
Pharmacokinetic interaction between maraviroc and fosamprenavir-ritonavir: an open-label, fixed-sequence study in healthy subjectsManoli Vourvahis, Anna Plotka, Laure Mendes da Costa, et al.
Journal of the International AIDS Society|November 14, 2014
First prospective comparison of genotypic vs phenotypic tropism assays in predicting virologic responses to Maraviroc (MVC) in a phase 3 study: MODERNJayvant Heera, Srinivas Valluri, Charles Craig, et al.
British Journal of Clinical Pharmacology|February 26, 2008
Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjectsEmma Andrews, Bharat D Damle, Annie Fang, et al.
Journal of Clinical Pharmacology|May 21, 2010
Pharmacokinetics of dexrazoxane in subjects with impaired kidney functionMichael E Brier, Shari K Gaylor, J Patrick McGovren, et al.
Clinical Pharmacology in Drug Development|June 25, 2020
Effect of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Intravenous RivipanselBrinda K Tammara, Kelly Ryan, Anna Plotka, et al.
Pediatric Research|June 14, 2018
Predictive value of early EEG for seizures in neonates with hypoxic-ischemic encephalopathy undergoing therapeutic hypothermiaMarie-Coralie Cornet, Archana Pasupuleti, Annie Fang, et al.
The New Microbiologica|April 30, 2019
First prospective comparison of genotypic versus phenotypic tropism assays in predicting virologic responses to maraviroc in a phase 3 studyJayvant Heera, Srinivas R Valluri, Charles Craig, et al.
Pageof 2